Enlivex Therapeutics (NASDAQ:ENLV) Stock Rating Lowered by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by equities research analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

Several other brokerages have also recently commented on ENLV. D Boral Capital cut Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 22nd. HC Wainwright restated a “buy” rating and set a $7.00 price target on shares of Enlivex Therapeutics in a research report on Tuesday, September 2nd. Finally, D. Boral Capital reaffirmed a “hold” rating on shares of Enlivex Therapeutics in a research note on Monday, November 24th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Enlivex Therapeutics currently has an average rating of “Hold” and a consensus target price of $10.00.

Enlivex Therapeutics Stock Performance

Enlivex Therapeutics stock opened at $0.75 on Friday. The company’s fifty day moving average price is $0.98 and its 200 day moving average price is $1.10. Enlivex Therapeutics has a 1 year low of $0.73 and a 1 year high of $2.10. The stock has a market capitalization of $18.16 million, a P/E ratio of -1.36 and a beta of 1.49.

Enlivex Therapeutics (NASDAQ:ENLV) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.03. Sell-side analysts predict that Enlivex Therapeutics will post -0.7 EPS for the current year.

Institutional Trading of Enlivex Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in ENLV. Susquehanna International Group LLP purchased a new position in Enlivex Therapeutics in the third quarter worth approximately $57,000. Jane Street Group LLC raised its holdings in Enlivex Therapeutics by 527.4% in the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after buying an additional 67,886 shares during the period. Finally, Citizens Financial Group Inc. RI acquired a new stake in shares of Enlivex Therapeutics during the third quarter valued at about $241,000. Institutional investors and hedge funds own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.